A multicenter phase 2 trial of olaparib (a PARP inhibitor) for the treatment of patients with a germline BRCA1/2 mutation and recurrent cancer achieved an ORR of 26.2% overall and an ORR of 21.7% for pancreatic cancer (NCT01078662).370 In the POLO trial and a randomized phase 3 trial for patients with metastatic pancreatic cancer with a germline BRCA1/2 mutation after at least 16 weeks of platinum-based chemotherapy, olaparib as a maintenance therapy achieved an ORR of 20% with a PFS median of 7.4 months, compared with 10% and 3.8 months in the placebo group (NCT02184195).14 Here, BRCA1 is linked to cancer.